Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Rhea-AI Summary
Nyxoah (NASDAQ: NYXH) will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16–19, 2026. Olivier Taelman, CEO, will deliver a corporate presentation on March 16, 2026 at 8:40 am ET. A webcast will be available in the Events section of Nyxoah's Investor Relations website.
The company will be available for one-on-one meetings with institutional investors. Nyxoah's investor presentation is accessible on the Shareholder Information section of the Investor Relations page.
Positive
- None.
Negative
- None.
News Market Reaction – NYXH
In the Mar 12 session, NYXH declined 3.90%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings date notice | Neutral | +0.5% | Scheduled Q4 and full-year 2025 results and conference call date. |
| Feb 27 | Ownership disclosure | Neutral | -1.5% | Transparency notification on 9.99% voting rights held by key shareholder. |
| Feb 25 | Capital structure update | Neutral | +5.6% | Update on total shares, voting rights, subscription rights and convertibles. |
| Feb 18 | Commercial expansion deal | Positive | -4.5% | MoU to expand Genio access and OSA therapy management in Middle East. |
| Jan 21 | Capacity expansion | Positive | +1.1% | Investment in 2,000 m² Belgian manufacturing facility and cleanroom. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent strategic and capital-structure announcements often produced mixed or contrary price reactions, with several positive or neutral updates followed by negative or divergent moves.
Over the last few months, Nyxoah has issued a mix of operational and capital-structure updates. On Jan 21, 2026, it announced Belgian manufacturing expansion, followed by a modest gain of 1.05%. A February MoU to broaden Genio access in the Middle East coincided with a -4.51% move, while later updates on voting rights and capital structure on Feb 25 saw a 5.62% rise. The upcoming earnings date release on Mar 5 had a small positive impact. Today’s conference participation fits into this ongoing investor communication and visibility push.
Key Terms
obstructive sleep apnea medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, which takes place March 16 – 19, 2026.
Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 16, 2026, at 8:40 am ET. A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website. The Company will be available for 1x1 meetings with institutional investors.
Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s
Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
